Abstract

Abstract:

The present invention relates to crystalline forms of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4­fluorophenyl)cyclopropane-1,1-dicarboxamide maleate represented by the following structural formula-1a, which is referred to as Cabozantinib maleate.

Formula-1a

The present invention also relates to crystalline form of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4­fluorophenyl)cyclopropane-1,1-dicarboxamide fumarate represented by the following structural formula-1b, which is referred to as Cabozantinib fumarate.

Formula-1b

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS